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Abstract: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it 
leads to significant morbidity and mortality, predominantly from ischemic stroke. Vitamin K 
antagonists, mainly warfarin, have been used for decades to prevent ischemic stroke in AF, but 
their use is limited due to interactions with food and other drugs, as well as the requirement 
for regular monitoring of the international normalized ratio. Rivaroxaban, a direct factor Xa 
inhibitor and the most commonly used non-vitamin K oral anticoagulant, avoids many of these 
challenges and is being prescribed with increasing frequency for stroke prevention in non-
valvular AF. Randomized controlled trial (RCT) data from the ROCKET-AF(Rivaroxaban once 
daily oral direct Factor Xa inhibition compared with vitamin K antagonism for prevention of 
stroke and embolism trial in atrial fibrillation) trial have shown rivaroxaban to be non-inferior to 
warfarin in preventing ischemic stroke and systemic embolism and to have comparable overall 
bleeding rates. Applicability of the RCT data to real-world practice can sometimes be limited 
by complex clinical scenarios or multiple comorbidities not adequately represented in the trials. 
Available real-world evidence in non-valvular AF patients with comorbidities – including renal 
impairment, acute coronary syndrome, diabetes mellitus, malignancy, or old age – supports 
the use of rivaroxaban as safe and effective in preventing ischemic stroke in these subgroups, 
though with some important considerations required to reduce bleeding risk. Patient perspectives 
on rivaroxaban use are also considered. Real-world evidence indicates superior rates of drug 
adherence with rivaroxaban when compared with vitamin K antagonists and with alternative 
non-vitamin K oral anticoagulants – perhaps, in part, due to its once-daily dosing regimen. 
Furthermore, self-reported quality of life scores are highest among patients compliant with 
rivaroxaban therapy. The generally high levels of patient satisfaction with rivaroxaban therapy 
contribute to overall favorable clinical outcomes.
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Introduction
Atrial fibrillation (AF) remains the most frequent sustained cardiac arrhythmia1 caus-
ing significant morbidity and mortality, and estimates suggest that its prevalence is 
increasing.1 AF is a chronic disorder that results in left atrial stasis and is thus associated 
with an increased risk of left atrial thrombus formation, and subsequent embolization 
to the brain causing stroke or systemic arterial thromboembolism. The main aims of 
the treatment for AF are the prevention of thromboembolic complications, such as 
stroke or systemic embolism (SE), and alleviation of symptoms.2 Current guidelines3 
recommend that care of patients with AF should take into account individual needs 
and preferences, with physicians offering patients a personalized package of care. 
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This includes a risk-based approach to stroke prevention and 
discussion of options for thromboprophylaxis.4
Historically, vitamin K antagonists (VKAs), mainly war-
farin, were the only available oral anticoagulants (OACs) for 
patients with AF. However, the narrow therapeutic window, 
which necessitates regular monitoring and dose adjustment, 
as well as the interactions with food, alcohol, and other 
drug–drug interactions limit the use of VKAs.4–6 Coagulation 
monitoring using the international normalized ratio (INR) 
is required,4,6 which has been the cornerstone of effective 
management of patients treated with VKA.
Non-vitamin K oral anticoagulants (NOACs), including 
factor Xa inhibitors rivaroxaban (Bayer AG, Leverkusen, 
Germany), apixaban (Bristol-Myers Squibb Co., New York 
City, NY, USA), and edoxaban (Daiichi Sankyo, Tokyo, 
Japan) and the direct thrombin inhibitor dabigatran, provide 
predictable pharmacological effects (onset and offset) that 
negate the need for monitoring,3,4 making this class of drugs 
a very attractive alternative to VKA. Since their introduction 
in the UK in 2008 (initially for thromboprophylaxis of deep 
venous thrombosis), prescriptions for NOACs have increased 
significantly, so that they now account for the majority of 
OAC prescriptions. In 2015, NOACs accounted for 56.5% 
of all OAC prescriptions, with rivaroxaban being the most 
frequently prescribed, followed by apixaban and dabigatran.7,8
Mode of action of rivaroxaban
Rivaroxaban is a direct oral factor Xa inhibitor. Factor Xa is 
produced via the intrinsic and extrinsic coagulation pathways 
and is the rate-limiting step in the propagation of thrombin 
generation. Indeed, factor Xa may be a better target than 
thrombin because it has fewer functions outside coagulation; 
thus, inhibition of factor Xa may cause fewer side effects.4 
Rivaroxaban acts as an anticoagulant by selectively, directly, 
and reversibly inhibiting free and clot-associated factor Xa in 
human plasma without binding to antithrombin.8,9 This results 
in the inhibition of the conversion of factor II (prothrombin) 
to factor IIa (thrombin). Rivaroxaban is 100,000-fold more 
selective for factor Xa than other biological proteases, such 
as thrombin, plasmin, factor VIIa, factor IXa, and activated 
protein C8,10 with no direct effect on platelet aggregation. 
Rivaroxaban is well tolerated, with a predictable pharmaco-
kinetic profile, without the need for laboratory monitoring.8
Pharmacodynamics
Rivaroxaban is well tolerated in healthy human subjects, with 
rapid onset of action and dose-proportional pharmacodynam-
ics and pharmacokinetics. Studies published more than a 
decade ago demonstrate that 20%–61% of inhibition of factor 
Xa occurs with rivaroxaban at doses of 5–80 mg. Maximum 
inhibition was seen to occur 1–4 hours after administration, 
and these effects lasted 5–12 hours.8,9,11 Both prothrombin 
time (PT) and activated partial thromboplastin time (aPTT) 
were also observed to be prolonged in a dose-dependent man-
ner.8,11 The respective prolongation of PT was 1.3–2.6 times 
the baseline value8,10 and around 1.5 times from baseline8,11 
for aPTT. These values were achieved within 1–4 hours after 
administration of rivaroxaban.8,9
Pharmacokinetics
After oral administration, rivaroxaban is absorbed rapidly 
and almost completely. Peak plasma concentrations (C
max
) 
are attained, and bioavailability is 80%–100% with the 10 
mg tablet dose.8,9,11,12 Area under the curve (AUC) was not 
affected by food intake at this dose.13 Nevertheless, the rate 
of absorption and bioavailability of a 20 mg tablet appears 
to decline without food. However, under fed conditions, 
there is a resultant increase in rivaroxaban concentration.13 
The pharmacokinetics of rivaroxaban do not appear to be 
affected by the type of food consumed.13 Approximately 90% 
of rivaroxaban is protein bound and its volume of distribu-
tion is about 1.36 L/kg.8,10 Rivaroxaban has no major active 
circulation metabolites and is metabolized in the liver by 
cytochrome P450 isoenzyme 3A4. It has a dual-mode excre-
tion process via renal elimination and a small amount via 
the fecal and biliary routes. Approximately 14%–31% of the 
drug is excreted unchanged in the urine.8,10,12 Rivaroxaban’s 
elimination half-life, at doses ranging from 5 mg daily to 
30 mg twice daily, is 5–9 hours.8,9,12 When administered to 
patients >75 years of age, patients with renal insufficiency (a 
creatinine clearance below 50 mL/minute), patients with low 
body weight (<50 kg), and patients with moderate hepatic 
disease (Child-Pugh class B), rivaroxaban was associated 
with reduced renal clearance, a higher (AUC) concentration, 
and increased factor Xa inhibition, indicating that dosage 
adjustments might be necessary for these patients.8,10,12,14
Real-world data on efficacy and 
safety in different patient groups
Overall efficacy and safety
The effectiveness of rivaroxaban in non-valvular AF (NVAF) 
was first shown in the ROCKET-AF (Rivaroxaban once daily 
oral direct Factor Xa inhibition compared with vitamin K 
antagonism for prevention of stroke and embolism trial in 
atrial fibrillation) trial,15 a large, multi-center, randomized, 
double-blind trial with 14,264 patients. Rivaroxaban was 
non-inferior to warfarin in preventing ischemic stroke and 
SE. Overall rates of major and clinically relevant non-major 
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bleeds were no different between the two groups, but there 
were more gastrointestinal bleeds in the rivaroxaban group 
than in the warfarin group (3.2% vs 2.2%, p<0.001). There 
were, however, significantly fewer intracranial or fatal bleeds 
in the rivaroxaban group than in the warfarin group (0.5% vs 
0.7% per year, HR 0.67, 95% CI: 0.47–0.93, p=0.02).
Randomized controlled trials (RCTs), the gold standard 
for assessing the efficacy and safety of a drug or interven-
tion, have a strict set of inclusion and exclusion criteria and 
use specific protocols for the treatment and follow-up of 
the patients involved.16 While this has obvious advantages 
when the efficacy and safety of a drug is being investigated, 
real-life patients outside of clinical trials may be more com-
plex than those participating in RCTs. Patients who would 
have been excluded due to frailty, bleeding risk, or specific 
comorbidities may nevertheless have a clear indication for 
anticoagulation. When newly licensed drugs are used in 
day-to-day practice, their efficacy and safety profile may be 
seen through observational studies, which can complement 
the findings of RCTs.17
The first such study to assess the effectiveness of rivar-
oxaban for stroke prevention in AF in the real-world setting 
was XANTUS (Xarelto® on prevention of stroke and non-
central nervous system systemic embolism in patients with 
non-valvular atrial fibrillation).18 The population of 6,784 
patients in XANTUS was at a lower risk of stroke, with 
a mean CHADS
2
 score of 2.0 compared with a CHADS
2
 
score of 3.5 in ROCKET-AF, and only 19% of patients 
had previously suffered a stroke, transient ischemic attack 
(TIA), or SE compared with 55% in ROCKET-AF. Fatal 
bleeding events were seen to occur at a rate of 0.2 per 100 
patient-years, intracranial hemorrhage at a rate of 0.4 events 
per 100 patient-years, and major gastrointestinal bleeding 
events at 0.9 events per 100 patient-years. Strokes occurred 
at a rate of 0.7 events per 100 patient-years (43 strokes in 
all, of which 32 were ischemic). In addition, a further eight 
patients experienced a systemic embolic event (0.1 events per 
100 patient-years). In summary, the rates of both bleeding 
complications and thromboembolic events were found to 
be low in real-life clinical practice amongst patients treated 
with rivaroxaban.18
A recent systematic review and meta-analysis17 of rivar-
oxaban use compared with dabigatran or warfarin in 17 real-
world studies of stroke prophylaxis in NVAF found that the 
effectiveness of rivaroxaban was similar to that of dabigatran 
in preventing stroke or systemic thromboembolism (HR 1.02; 
95% CI: 0.91–1.13) though with higher major bleeding (HR 
1.38; 95% CI: 1.27–1.49) and GI bleeding (HR 1.33; 95% 
CI: 1.18–1.48). Rates of acute myocardial infarction and 
intracerebral hemorrhage were comparable. Rivaroxaban was 
more effective than warfarin in reducing the rate of stroke or 
systemic thromboembolism (HR 0.75; 95% CI: 0.64–0.84). 
As was seen in the ROCKET trial, there were more GI bleeds 
in the rivaroxaban group (HR 1.2; 95% CI: 1.07–1.33) and 
fewer intracerebral bleeds (HR 0.54; 95% CI: 0.43–0.64). 
There was no significant difference in all-cause mortality.17
Real-world studies, such as registries and database 
analyses, can provide helpful evidence to aid management 
decisions where RCT data may be lacking. Data from 
such databases have recently been published, including the 
Dresden NOAC registry, which supports the short-term peri-
procedural interruption of NOAC therapy as safe. Interest-
ingly, in this same registry, analysis of patients who sustained 
a major bleeding event on an NOAC indicated that those 
patients who later recommenced OAC therapy, either with 
an NOAC or a VKA, had significantly lower mortality and a 
lower rate of recurrent major bleeding or thromboembolism 
than those who remained off OAC therapy. Real-world studies 
such as these can serve to complement the data available from 
RCTs, and inform decision making, including in complicated 
clinical scenarios.19
The XANTUS population generally had fewer comor-
bidities than were seen in the ROCKET-AF trial. Subgroup 
analyses from ROCKET-AF have shown broad consistency in 
efficacy and safety across a range of different patient groups. 
However, special considerations are appropriate when pre-
scribing rivaroxaban in some patient groups due to the greater 
risk of bleeding complications. These are discussed below.
Renal impairment
Patients with AF and renal disease are at a greater risk of 
both cerebrovascular ischemic events and bleeding events 
than those without renal impairment. At the milder end of the 
renal dysfunction spectrum, the trend is toward a greater risk 
of ischemic events,20 whereas those with severe or end-stage 
renal disease are more prone to hemorrhage, predominantly 
due to platelet dysfunction.21
Furthermore, since one-third of the administered rivar-
oxaban dose is excreted via the kidneys, dose reduction is 
required if there is renal dysfunction (creatinine clearance 
15–49 mL/minute), to avoid high plasma levels.22 These 
patients should be prescribed 15 mg once per day, instead of 
the 20 mg once per day dose for those with preserved renal 
function (creatinine clearance ≥50 mL/minute). Rivaroxa-
ban should be avoided altogether in end-stage renal disease 
(creatinine clearance <15 mL/minute).
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It is not uncommon for patients to be prescribed or left 
on an inappropriately high or low dose of rivaroxaban for 
their level of renal function, and where dose reduction is 
not undertaken in renal dysfunction, there is an excess of 
major bleeding complications. By the same token, those 
prescribed a renal dose despite normal renal function are 
at an increased risk of stroke.23 To ensure that patients are 
commenced and remain on the correct dose of rivaroxaban, 
renal function should be checked at baseline, annually there-
after, and in circumstances where there may be deterioration 
in renal function, such as with infection, dehydration, or 
surgery.24
Though end-stage renal disease is a contraindication to 
rivaroxaban use, its safety and efficacy in mild or moderate 
renal impairment is supported by a recent meta-analysis, 
in which NOAC therapy was compared to warfarin in this 
patient population. Ischemic stroke rates were found to be 
lower with NOACs in patients with mild renal impairment 
(relative risk [RR] 0.79; 95% CI: 0.68–0.91) and moderate 
renal impairment (RR 0.80; CI: 0.69–0.92). Major bleeding 
rates were also lower in mild (RR 0.86; CI: 0.77–0.95) and 
moderate renal impairment (RR 0.73; CI: 0.65–0.82).25
In another recent study, rivaroxaban, in particular, was 
shown to have a favorable risk profile in patients with 
renal dysfunction, with lower rates of eGFR deterioration, 
doubling of serum creatinine, and acute kidney injury 
episodes than were observed with warfarin. Other NOACs 
also compared favorably with warfarin, though not to the 
same extent.26
Elderly patients
The prevalence of AF increases with age, and it is estimated 
to affect at least 10% of those over the age of 75 years.27 
Concern over bleeding complications has led to the underuse 
of anticoagulation in the elderly, leaving them at a greater risk 
of disabling ischemic stroke. Although the elderly are also at 
an increased risk of hemorrhage with oral anticoagulation, 
the benefit of ischemic stroke reduction exceeds the risk of 
hemorrhage for most patients.28 The median age of patients in 
the ROCKET-AF trial was 73 years (interquartile range 65–78 
years),28 and the mean age in XANTUS was 71.5 years, with 
37% of patients being >75 years old.28 The safe and effective 
use of rivaroxaban in the elderly is well supported by avail-
able data, but care must be taken to address comorbidities 
that may increase the likelihood of bleeding complications 
and which are more prevalent in the older population, such as 
the risk of falls, renal dysfunction requiring dose reduction, 
and adequate control of hypertension.
Acute coronary syndrome and 
percutaneous coronary intervention
Around 15% of patients with pre-existing AF also have 
an acute coronary syndrome (ACS) event.29 Though both 
pathologies involve thrombosis, their pharmacological man-
agement differs. As a means of preventing ischemic stroke, 
OAC is superior to dual antiplatelet therapy (a combination 
of aspirin plus one of clopidogrel, ticagrelor, or prasugrel).30 
Meanwhile, dual antiplatelet therapy is superior to OAC with 
warfarin for preventing stent thrombosis in patients with 
ACS.31 Those with concomitant AF and ACS may therefore 
have an indication for both dual antiplatelet therapy and 
OAC – so-called triple therapy.
The bleeding risk with triple therapy is not inconsider-
able, particularly when used for prolonged periods, with one 
meta-analysis involving a total of 1,349 patients indicating a 
2.2% 30-day risk of major bleeding rising to 12% at 1 year,32 
highlighting the need to minimize the duration of triple 
therapy to keep the risk–benefit balance favorable.
The 2016 European Society of Cardiology (ESC) Guide-
lines for the Management of Atrial Fibrillation3,33 recommend 
that in patients with ACS and AF at low bleeding risk (HAS 
BLED ≤2), initial triple therapy comprising an NOAC and 
aspirin (75–100 mg/day) and clopidogrel (75 mg/day) should 
be considered for 6 months, irrespective of stent type (bare 
metal stent or drug-eluting stent), followed by (N)OAC and 
aspirin (75–100 mg/day) or clopidogrel (75 mg/day) contin-
ued up to 12 months. Furthermore, in patients requiring OAC 
at high bleeding risk (HAS BLED ≥3), triple therapy of (N)
OAC and aspirin (75–100 mg/day) and clopidogrel (75 mg/
day) should be considered for a duration of 1 month followed 
by (N)OAC and aspirin (75–100 mg/day) or clopidogrel (75 
mg/day) irrespective of clinical setting and stent type until 
12 months post ACS. These guidelines are supported by the 
recent 2017 ESC Guidelines for the management of acute 
myocardial infarction in patients presenting with ST-segment 
elevation.34
The recent PIONEER AF-PCI (Study Exploring Two 
Strategies of Rivaroxaban and One of Oral Vitamin K 
Antagonist in Patients With Atrial Fibrillation Who Undergo 
Percutaneous Coronary Intervention) trial35 randomized 
2,124 patients with NVAF who had undergone percutaneous 
coronary intervention (PCI) to one of three groups. Group 1 
received rivaroxaban 15 mg once daily with a P2Y
12
 inhibitor 
(clopidogrel or ticagrelor) for a total of 12 months, group 2 
were given rivaroxaban 2.5 mg b.i.d. with dual antiplatelet 
therapy for 1, 6, or 12 months, and group 3 were given a 
VKA plus dual antiplatelet therapy for 1, 6, or 12 months. 
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There was a significantly reduced rate of bleeding compli-
cations, including major, minor, or other bleeds requiring 
medical attention, in the two rivaroxaban groups compared 
with VKA group (16.8% in group 1, 18.0% in group 2, and 
26.7% in group 3). There was no significant difference seen 
in cardiovascular mortality between the groups or in the rates 
of stroke. In fact, the study was not sufficiently powered to 
find a difference in rates of strokes. With safety having been 
established, further work is needed to determine adequate 
efficacy as far as stroke prevention is concerned.35
Four other trials in this patient population are currently 
ongoing: RE-DUAL PCI (Evaluation of Dual Therapy With 
Dabigatran vs Triple Therapy With Warfarin in Patients With 
AF That Undergo a PCI With Stenting),36 AUGUSTUS (A 
Study of Apixaban in Patients With Atrial Fibrillation, Not 
Caused by a Heart Valve Problem, Who Are at Risk for 
Thrombosis [Blood Clots] Due to Having Had a Recent 
Coronary Event, Such as a Heart Attack or a Procedure to 
Open the Vessels of the Heart), SAFE-A (Rationale and 
design of the SAFE-A study: SAFety and Effectiveness trial 
of Apixaban use in association with dual antiplatelet therapy 
in patients with atrial fibrillation undergoing percutaneous 
coronary intervention), and ENTRUST-AF PCI (Evaluation 
of the safety and efficacy of an edoxaban-based antithrom-
botic regimen in patients with atrial fibrillation following 
successful percutaneous coronary intervention (PCI) with 
stent placement). These trials will aim to determine the effi-
cacy and safety of three other NOACs in combination with 
antiplatelet therapy compared with warfarin and antiplatelet 
therapy. RE-DUAL PCI will compare dabigatran plus P2Y
12
 
inhibitor therapy to triple therapy with warfarin, aspirin, 
and a P2Y
12
 inhibitor.36 The AUGUSTUS trial will compare 
apixaban plus a P2Y
12 
inhibitor with or without aspirin, with 
warfarin plus P2Y
12 
inhibitor with or without aspirin (https://
clinicaltrials.gov/ct2/show/NCT02415400). The SAFE-A 
trial will be comparing 1 month vs 6 months of triple therapy 
comprising apixaban plus P2Y
12 
inhibitor plus aspirin after 
drug-eluting stent implantation in patients with NVAF.37 The 
ENTRUST-AF PCI trial will compare the combination of 
edoxaban plus P2Y
12
 inhibitor against the combination of 
warfarin, aspirin, and a P2Y
12
 inhibitor in patients with AF 
undergoing PCI.38 Hopefully, these trials will provide further 
useful data to enable informed clinical decision making in 
this important patient population.
Diabetes mellitus
Diabetes and AF often coexist, and diabetes itself is a sig-
nificant risk factor for ischemic stroke. Longer duration of 
diabetes is associated with a higher risk of ischemic stroke, 
while the degree of strict glycemic control does not appear 
to be as important.39 Diabetes alone, without coexisting 
renal dysfunction, does not increase the risk of bleeding 
complications from OAC therapy, and German registry data 
indicate that diabetes is one of the several risk factors for the 
discontinuation of rivaroxaban therapy (HR 1.39; 95% CI: 
1.06–1.82; p=0.018).40 Given the greater risk of ischemic 
stroke without an increase in bleeding risk from rivaroxa-
ban therapy, it may be appropriate to give special attention 
to address any concerns that may limit adherence in such 
patients. An on-going post-marketing safety surveillance 
observational study in nearly 45,000 people with NVAF 
found that the incidence of major bleeding in diabetics was 
generally consistent with reports from the ROCKET AF 
subgroup analysis.41
Malignancy
Active cancer is a hypercoagulable state, which confers an 
increased risk of ischemic stroke, but there may also be a 
greater risk of bleeding events with local tumor invasion. 
Where such patients also have AF, decisions on anticoagula-
tion can prove challenging.42 Patients with serious concomi-
tant illness associated with a life expectancy of <2 years were 
excluded from ROCKET-AF, although rivaroxaban has been 
shown in other studies to have satisfactory safety and efficacy 
for treating venous thromboembolic disease in the context 
of malignancy.43
A recent registry of 163 patients with NVAF and active 
malignancy receiving rivaroxaban showed similar safety and 
efficacy for rivaroxaban as that shown in ROCKET-AF, albeit 
in a much smaller cohort of patients.42 After adjustment for 
risk factors, in this population with active malignancy with 
some 59% of patients with stage IV disease, the cumulative 
incidence of stroke at 1 year was 1.4%, major bleeding was 
1.2%, clinically relevant non-major bleeding was 14%, and 
death was 22.6%.42 The risk of clinically relevant non-major 
bleeding, leading to discontinuation of anticoagulation at 1 
year was 14.0% (95% CI: 4.2–22.7%). The data available are 
limited, but indicate that rivaroxaban can be considered for 
NVAF patients with cancer.
Patient-focused perspectives
Adherence
The degree to which a prescribed drug is taken as intended 
by the prescribing clinician has a significant impact on both 
efficacy and safety, and adherence is frequently poor with 
cardiovascular medicines of any kind and among all patient 
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groups.44 Common reasons for this include often complicated 
dosing regimens, large pill size, fear of side effects, forgetful-
ness, and a lack of understanding of the intended benefits.45
For some, the additional specific inconveniences associ-
ated with VKA such as warfarin – having to undergo regular 
blood tests, attend anticoagulation clinic appointments, avoid 
specific foods and their interactions with alcohol, drug inter-
actions – also contribute to poor adherence.45 The inevitable 
consequence of poor adherence to the prescribed regimen is 
suboptimal time in therapeutic range (TTR), which carries 
with it an excess risk of thromboembolic events and bleed-
ing.46 Even with regular INR monitoring, TTR is still low in a 
significant proportion of patients, and up to three quarters of 
patients taking warfarin for AF who present with an ischemic 
stroke have a subtherapeutic INR at the time of the event.47
The advent of NOACs has removed some of the chal-
lenges associated with VKAs, including the need for regular 
blood test monitoring. NOACs have the advantage of being 
given in a fixed dosing regimen, for example, rivaroxaban 
20 mg once daily for patients with creatinine clearance >50 
mL/minute, or a reduced dose of 15 mg once daily in patients 
with creatinine clearance 15–50 mL/minute.
Therefore, as might be expected, adherence to OAC is 
better in patients taking NOACs than that in patients on a 
VKA. An Australian study of 2,819 patients with NVAF 
(1,471 taking NOACs – 15% apixaban, 44% dabigatran, 
41% rivaroxaban – and 1,348 taking warfarin), looked at the 
proportion of patients not filling a first repeat prescription 
and discontinuing the treatment within 12 months.48 In the 
NOAC group, 9% failed to fill a first repeat prescription and 
30% discontinued within 12 months compared with 14% 
and 62%, respectively, in the warfarin group. Regression 
analysis adjusted for age, sex, heart failure, diabetes, and 
hypertension, showed that overall, patients on warfarin were 
2.5 times more likely to stop taking their prescribed anti-
coagulant than were patients on an NOAC (HR 2.47, 95% 
CI: 2.19–2.79).48 Danish experience shows a similar story. 
Registry data from 46,675 patients with NVAF were used 
to compare adherence with VKA to that seen with NOACs. 
Accordingly, 57.3% of patients were taking a VKA, 29.8% 
dabigatran, 8.5% rivaroxaban, and 4.4% apixaban.49 The 
highest levels of adherence, as measured by the Proportions 
of Days Covered (PDC) >80%, were seen in patients taking 
rivaroxaban. In comparison with rivaroxaban, the odds ratio 
for a PDC >80% for apixaban was 0.79 (95% CI: 0.69–0.92), 
for dabigatran was 0.72 (95% CI: 0.66–0.80), and for VKA 
was 0.76 (95% CI: 0.69–0.83). Again, using rivaroxaban 
as a reference, the hazard ratio for repeat prescription gaps 
of between 7 and 89 days for apixaban, was 1.52 (95% CI: 
1.36–1.69), for dabigatran, 1.72 (95% CI: 1.60–1.85), and 
for VKA, 2.36 (95% CI: 2.20–2.52). Furthermore, in 11.5% 
of patients taking VKA, refill gaps of longer than 89 days 
were seen.49
Adherence to rivaroxaban also compares favorably with 
that seen with other NOACs. A study of 14,469 patients with 
NVAF, comparing adherence with once-daily rivaroxaban 
(11,477 patients) and twice-daily apixaban (2,992 patients) 
at 90 and 180 days, found that rivaroxaban users had a 
higher PDC >80% than apixaban users at 90 days (85.3% vs 
79.9%, p<0.001) and at 180 days (75.8% vs 72.2%, p=0.001). 
Repeat prescription gaps of at least 5 and 10 days were also 
lower in the rivaroxaban group than in the apixaban group 
(54.2% vs 62.4% [p<0.001], and 40% vs 49.2% [p<0.001] 
respectively).50 Similar findings have been reported in com-
parisons of rivaroxaban with dabigatran, another twice-daily 
NOAC.51,52 It may be seen that adherence to NOAC therapy 
is imperfect, but significantly better than with warfarin, and 
between NOACs – significantly better with the once-a-day 
rivaroxaban.
Once-daily dosing
The once-daily dosing regimen with rivaroxaban has sig-
nificant advantages over twice a day regimens. A patient’s 
understanding of dosing instructions is fundamental to the 
drug being taken as intended and is understandably greater 
with simpler dosing regimens. Understanding of dosing 
instructions and compliance are reduced both with more 
complex dosing regimens and with an increasing number of 
other medications being taken.53
Furthermore, patients taking twice-daily drugs often do 
not space them out at the desired 12-hour dosing intervals, 
with intervals in practice ranging between as little as 1 hour 
and as many as 18 hours.54 This can lead to greater variabil-
ity in drug plasma concentrations and the potential to leave 
patients at a greater risk of either bleeding or thromboembolic 
events. On the other hand, this needs to be weighed up against 
the more forgiving pharmacokinetics of twice-daily drugs in 
the event of occasional doses being missed.55
Whichever anticoagulant is prescribed, improved adher-
ence and better outcomes are seen in patients who are 
adequately involved in the decision-making process. The 
question of once-daily vs twice-daily dosing should be 
an important part of the discussion when conferring with 
patients about the anticoagulant they take.24 The 2016 ESC3 
guidelines highlight the importance of patient education in 
empowering them to support the management of their AF.
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Satisfaction and quality of life
Closely tied to adherence levels is patient satisfaction with 
the prescribed medication, and its perceived impact on 
quality of life (QOL). SAFARI (Satisfaction/Quality of Life 
With Rivaroxaban in Stroke Prevention in Atrial Fibrillation 
Indication) is a French prospective, multicenter observational 
study of 405 patients with NVAF who switched from VKA to 
rivaroxaban, intended to show whether, in real-life practice, 
patient satisfaction is improved after making the change from 
VKA to rivaroxaban.56 Patient satisfaction levels and QOL 
were assessed by means of the validated 15-item Anti-Clot 
Treatment Scale (ACTS) (including the 12-item ACTS Bur-
dens scale, and the 3-item ACTS Benefits scale, with higher 
numbers indicating greater levels of satisfaction) and the 
validated SF-36 health survey. Assessment was undertaken 
at baseline, 1, 3, and 6 months. There was an improvement in 
satisfaction, with baseline burden scores rising from a mean 
of 46.5 at baseline to 54.8 at 6 months (p<0.001), and baseline 
benefit scores rising from a mean of 10.4 to 10.8 at 6 months 
(p=0.02).56 Statistical significance was reached, albeit with 
only a modest effect size. Slight improvements were seen in 
patients’ QOL but did not reach statistical significance. A total 
of 106 treatment-related adverse events were experienced by 
81 patients (19.7%), of which around half led to rivaroxaban 
discontinuation, the most common being gastrointestinal 
problems such as gingival and digestive bleeding. There 
were 11 serious bleeding events attributed to the rivaroxaban, 
including one death from hemorrhagic stroke.56
The much larger, international registry study, XANTUS, 
analyzed data from 1,291 patients with NVAF making the 
change from VKA to rivaroxaban.18 The mean baseline ACTS 
burden score was 50.51±8.42 and the mean benefit score was 
10.30±2.70. Changes in these scores at 3-month follow-up 
were reported as least-squared mean differences and were 
improved by 4.38 points (95% CI: 2.53–6.22, p<0.0001) for 
the ACTS burden score, and 1.01 points (95% CI: 0.27–1.75, 
p=0.0075) for the benefit score.57
The Swiss STAR (Initiation of rivaroxaban in patients 
with non-valvular atrial fibrillation at the primary care level: 
the Swiss Therapy in Atrial Fibrillation for the Regulation of 
Coagulation) study of 537 patients with NVAF in the primary 
care setting also demonstrated improvements in patient satis-
faction with treatment after commencement of rivaroxaban.58 
In this study, 56% of patients were switched from VKA 
to rivaroxaban (STR group), predominantly to avoid the 
need for routine INR monitoring, and 44% of patients were 
VKA naïve (VN group). Patient satisfaction was assessed 
on a 6-point scale with higher numbers indicating higher 
satisfaction. In the STR group, it rose from 3.6±1.4 on VKA 
therapy to 5.5±0.8 on rivaroxaban at 3 months (p<0.001). 
Such an improvement might be expected given that these 
patients had made the change to an NOAC in order not to 
have the inconvenience of regular blood tests, but a similar 
satisfaction level was also seen in the VN group: 5.4±0.9. 
Physician satisfaction was also assessed, and it improved 
from 3.9±1.3 to 5.4±0.9 in the STR group and was 5.5±0.7 
in the VN group. During the comparatively short follow-up 
period of 3 months, rivaroxaban was discontinued in 30 
(5.6%) patients, predominantly due to side effects. There 
were 1 ischemic stroke, 2 major non-fatal bleeds, and 11 
minor bleeds.58
QOL is closely associated with satisfaction and adher-
ence, as found in a Spanish multicenter (including primary 
and secondary care centers), prospective study of 412 patients 
taking rivaroxaban for NVAF. At 6 months, there was no 
significant difference in QOL between the compliant and 
non-compliant groups, but after 12 months the difference 
was marked, with mean QOL scores of 124.67 (SD 30.78) 
in the non-compliant group and 83.47 (SD 26.44) in the 
compliant group (p<0.01), with higher scores indicating 
a worse QOL. Other predictors of poor QOL found were 
polypharmacy, older age, previous treatment with a VKA, 
and comorbidities.59
Conclusion
Symptom control and prevention of major complications 
such as thromboembolism are the two main aims of effective 
AF management. In preventing stroke and SE, both the ESC 
and National Institute of Clinical Excellence (NICE) guide-
lines recommend NOAC over VKA in patients with NVAF 
in whom anticoagulant therapy is indicated. Rivaroxaban is 
an NOAC approved for and indicated to reduce the risk of 
stroke and SE in patients with NVAF, and has been shown 
to be non-inferior in this regard to VKA. Rivaroxaban has 
been shown to be well tolerated with superior safety with 
regards to bleeding events compared with warfarin. Trial data 
from ROCKET-AF are supported by a huge wealth of data 
from post-marketing surveillance registries with rivaroxaban 
showing safety and efficacy, in line with what was seen in 
clinical trials. Such registries also provide important insights 
into the safety of rivaroxaban use in NVAF patients with 
comorbidities, including renal impairment, ACS, diabetes 
mellitus, malignancy, or old age. Post-marketing observa-
tional studies of rivaroxaban complement the outcomes of 
landmark trials through the use of unselected real-world 
populations and conditions and show that rivaroxaban use 
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in patients with NVAF is associated with a low risk of major 
bleeding and stroke.
Disclosure
DAG has received honoraria from Bayer (UK) PLC and 
AstraZeneca. The authors report no other conflicts of  interest 
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